Aurobindo Pharma Nears Breakout Zone, Eyes ₹1,531 Target: SEBI RA WealthFino

Published 22-05-2025, 01:07 pm
© Reuters Aurobindo Pharma Nears Breakout Zone, Eyes ₹1,531 Target: SEBI RA WealthFino

Stocktwits - Aurobindo Pharma (NSE:ARBN) is approaching a crucial technical point, which may lead to a breakout, according to SEBI-registered research firm WealthFino.

According to WealthFino’s analysis, the stock consolidates through higher lows while challenging a trendline resistance level.

At the time of writing, Aurobindo Pharma shares were trading at ₹1,182.60, down 1.79% or ₹21.50 on the day.

If the stock maintains its position above ₹1,225, backed by substantial volume, it will validate a bullish breakout that will propel the stock toward its target levels of ₹1,349, followed by ₹1,420, and possibly reaching ₹1,531.

WealthFino said the price above the 9-day exponential moving average (EMA) shows signs of short-term bullish momentum.

The research firm pointed to the ₹1,145–₹1,155 range as an attractive area for additional purchases because buyers have historically shown interest in this zone.

According to WealthFino, the market will likely maintain its current sideways trend or pull back slightly unless the trendline breaks decisively.

A fall below ₹1,098 shows market weakness, which might trigger additional price decreases.

On Stocktwits, retail sentiment was ‘bullish’ amid ‘normal’ message volume.

The stock has declined 12.6% so far in 2025.

This content is provided by Stocktwits

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.